Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

Is the COVID-19 vaccine safe and effective for infants and young children? Here's what parents need to know about vaccinating their babies and toddlers against COVID-19.

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

According to Pfizer and BioNTech, this is the first time that an mRNA-based flu vaccine has started a phase 3 efficacy trial. Its rival Moderna said earlier this month, however, that it has ...

Moderna's study looked at the vaccine in adults aged 50 and older, while Pfizer/BioNTech's trial focused on adults aged 18 to 64. Other rivals, meanwhile, include Sanofi/Novavax, which are ...

On Friday, February 7, a hearing took place in the Montana state legislature on a bill that would ban the use of mRNA ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald ...

But Truist analysts Asthika Goonewardene and Karina Rabayeva said that they believe the declining outlook on COVID-19 vaccination rates in 2025 may be restricted to just Moderna’s vaccine, perhaps ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Moderna launched RSV vaccine mResvia in 2024 as the third-to-market product behind GSK and Pfizer vaccines. However, the firm's pipeline progress could lead to 2025-27 launches for a covid/flu ...

Drugmaker pauses HPV Gardasil exports as rival Pfizer gets boost from better than expected Covid vaccine and pill sales ...